Sickle-Cell Disease

Clinical compound rPSGL-Ig licensed for development and commercialization

Published in Blood Weekly, February 5th, 2004

Thios Pharmaceuticals, Inc., announced the signing of a licensing agreement with Wyeth granting Thios exclusive worldwide rights to develop and commercialize the compound rPSGL-Ig, a recombinant form of the human PSGL-1 glycoprotein.

Thios has renamed the rPSGL-Ig compound TS1.

"This agreement provides an important strategic opportunity for Thios to move quickly into clinical trials with a sulfated therapeutic. TS1 has an outstanding safety profile with over 500 patients treated safely, complements our existing pipeline of potential products and enhances our leadership position in the sulfation field," said Bruce A. Hironaka, president and chief...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2004-02-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry